Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses.

Daum RS, Miller LG, Immergluck L, Fritz S, Creech CB, Young D, Kumar N, Downing M, Pettibone S, Hoagland R, Eells SJ, Boyle MG, Parker TC, Chambers HF; DMID 07-0051 Team.

N Engl J Med. 2017 Jun 29;376(26):2545-2555. doi: 10.1056/NEJMoa1607033.

PMID:
28657870
2.

Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections.

Miller LG, Daum RS, Creech CB, Young D, Downing MD, Eells SJ, Pettibone S, Hoagland RJ, Chambers HF; DMID 07-0051 Team.

N Engl J Med. 2015 Mar 19;372(12):1093-103. doi: 10.1056/NEJMoa1403789.

3.

Staphylococcus aureus bacteremia at 5 US academic medical centers, 2008-2011: significant geographic variation in community-onset infections.

David MZ, Daum RS, Bayer AS, Chambers HF, Fowler VG Jr, Miller LG, Ostrowsky B, Baesa A, Boyle-Vavra S, Eells SJ, Garcia-Houchins S, Gialanella P, Macias-Gil R, Rude TH, Ruffin F, Sieth JJ, Volinski J, Spellberg B.

Clin Infect Dis. 2014 Sep 15;59(6):798-807. doi: 10.1093/cid/ciu410. Epub 2014 May 30.

4.

The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit.

Wohl DA, Kendall MA, Feinberg J, Alston-Smith B, Owens S, Chafey S, Marco M, Maxwell S, Benson C, Keiser P, van der Horst C, Jacobson MA; A5030 Study Team.

PLoS One. 2013 Nov 15;8(11):e78676. doi: 10.1371/journal.pone.0078676. eCollection 2013.

5.

Concurrent epidemics of skin and soft tissue infection and bloodstream infection due to community-associated methicillin-resistant Staphylococcus aureus.

Tattevin P, Schwartz BS, Graber CJ, Volinski J, Bhukhen A, Bhukhen A, Mai TT, Vo NH, Dang DN, Phan TH, Basuino L, Perdreau-Remington F, Chambers HF, Diep BA.

Clin Infect Dis. 2012 Sep;55(6):781-8. doi: 10.1093/cid/cis527. Epub 2012 Jun 5.

6.

No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy.

Gandhi RT, Coombs RW, Chan ES, Bosch RJ, Zheng L, Margolis DM, Read S, Kallungal B, Chang M, Goecker EA, Wiegand A, Kearney M, Jacobson JM, D'Aquila R, Lederman MM, Mellors JW, Eron JJ; AIDS Clinical Trials Group (ACTG) A5244 Team.

J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):229-35. doi: 10.1097/QAI.0b013e31823fd1f2.

7.

Failure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the C-terminus of HIV-1 reverse transcriptase.

Brehm JH, Lalama CM, Hughes MD, Haubrich R, Riddler SA, Sluis-Cremer N, Mellors JW; AIDS Clinical Trials Group Study A5142 Protocol Team.

J Acquir Immune Defic Syndr. 2011 Apr;56(4):344-8. doi: 10.1097/QAI.0b013e31820cf029.

8.

Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030.

Wohl DA, Kendall MA, Andersen J, Crumpacker C, Spector SA, Feinberg J, Alston-Smith B, Owens S, Chafey S, Marco M, Maxwell S, Lurain N, Jabs D, Benson C, Keiser P, Jacobson MA; A5030 Study Team.

HIV Clin Trials. 2009 May-Jun;10(3):143-52. doi: 10.1310/hct1003-143.

9.

Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.

Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, Garren KW, Butcher DL, Rooney JF, Haas DW, Mellors JW, Havlir DV; AIDS Clinical Trials Group (ACTG) A5142 Study Team.

AIDS. 2009 Jun 1;23(9):1109-18. doi: 10.1097/QAD.0b013e32832b4377.

10.

Class-sparing regimens for initial treatment of HIV-1 infection.

Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Lalloo UG, Murphy RL, Swindells S, Havlir D, Mellors JW; AIDS Clinical Trials Group Study A5142 Team.

N Engl J Med. 2008 May 15;358(20):2095-106. doi: 10.1056/NEJMoa074609.

11.

The influence of muscle type and dystrophin deficiency on murine expression profiles.

Haslett JN, Kang PB, Han M, Kho AT, Sanoudou D, Volinski JM, Beggs AH, Kohane IS, Kunkel LM.

Mamm Genome. 2005 Oct;16(10):739-48. Epub 2005 Oct 29.

PMID:
16261416
12.

Systemic delivery of human microdystrophin to regenerating mouse dystrophic muscle by muscle progenitor cells.

Bachrach E, Li S, Perez AL, Schienda J, Liadaki K, Volinski J, Flint A, Chamberlain J, Kunkel LM.

Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3581-6. Epub 2004 Mar 1.

13.

Skeletal muscle engraftment potential of adult mouse skin side population cells.

Montanaro F, Liadaki K, Volinski J, Flint A, Kunkel LM.

Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9336-41. Epub 2003 Jul 28.

14.

The dystrophin associated protein complex in zebrafish.

Guyon JR, Mosley AN, Zhou Y, O'Brien KF, Sheng X, Chiang K, Davidson AJ, Volinski JM, Zon LI, Kunkel LM.

Hum Mol Genet. 2003 Mar 15;12(6):601-15.

PMID:
12620966

Supplemental Content

Loading ...
Support Center